Cargando…
Peptide Modification Diminishes HLA Class II-restricted CD4(+) T Cell Recognition of Prostate Cancer Cells
Prostate cancer poses an ongoing problem in the western world accounting for significant morbidity and mortality in the male population. Current therapy options are effective in treating most prostate cancer patients, but a significant number of patients progress beyond a manageable disease. For the...
Autores principales: | Doonan, Bently P., Amria, Shereen, Bethard, Jennifer R., Banik, Narendra L., Hathaway-Schrader, Jessica D., Haque, Azizul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738740/ https://www.ncbi.nlm.nih.gov/pubmed/36499557 http://dx.doi.org/10.3390/ijms232315234 |
Ejemplares similares
-
GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition
por: Hathaway-Schrader, Jessica D., et al.
Publicado: (2022) -
Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design
por: Doonan, Bently P, et al.
Publicado: (2015) -
HLA Class II Defects in Burkitt Lymphoma: Bryostatin-1-Induced 17 kDa Protein Restores CD4+ T-Cell Recognition
por: Hossain, Azim, et al.
Publicado: (2011) -
Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma
por: Norton, Duncan L., et al.
Publicado: (2009) -
Multiple Defects Impair the HLA Class II Antigen Presentation Capacity of Burkitt Lymphoma
por: God, Jason M., et al.
Publicado: (2016)